Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Neuro-ophthalmology · Autosomal Dominant Optic Atrophy

Do Supplements Like CoQ10 or NAD+ Work for ADOA?

At a Glance

There is currently no clinical evidence proving that supplements like Idebenone, CoQ10, or NAD+ precursors are effective treatments for Autosomal Dominant Optic Atrophy (ADOA). Patients should consult a neuro-ophthalmologist before taking unproven over-the-counter mitochondrial supplements.

In this answer

4 sections

01

The Difference Between LHON and ADOA Treatments

02

CoQ10 and “Mitochondrial Cocktails”

03

The Promise of NAD+ Precursors

04

Moving Forward

At this time, there is no clinical evidence proving that supplements like Idebenone, CoQ10, or NAD+ precursors are effective for treating Autosomal Dominant Optic Atrophy (ADOA) [1][2]. While some of these supplements are used to treat a different mitochondrial eye disease called Leber Hereditary Optic Neuropathy (LHON), they affect the cells differently and are not a standard, recommended treatment for ADOA [3][4].

The Difference Between LHON and ADOA Treatments

Because LHON and ADOA are both mitochondrial optic neuropathies (conditions where the energy-producing centers of the cells in the optic nerve do not work properly), people naturally wonder if the same treatments will work for both.

Idebenone, a synthetic version of Coenzyme Q10 (CoQ10), is an approved treatment for LHON in some regions [5][6]. It works for LHON because it can bypass the specific cellular defect (a failure in “Complex I” of the energy chain) causing that disease [5][7].

However, ADOA is usually caused by mutations in the OPA1 gene, which creates a different type of mitochondrial problem. Early laboratory research has shown that Idebenone is largely ineffective at protecting the specific optic nerve cells affected by OPA1 mutations [8]. Currently, there is a lack of clinical evidence showing that Idebenone improves or stabilizes vision for patients with ADOA [4].

CoQ10 and “Mitochondrial Cocktails”

Sometimes, doctors prescribe a mitochondrial cocktail—a combination of supplements like CoQ10, L-carnitine, and B-vitamins—for general mitochondrial disorders [9][10].

While there are isolated case reports of these cocktails providing minor benefits in some generalized conditions [11][12], there are no dedicated clinical trials confirming that CoQ10, Idebenone, or supplement cocktails improve vision or slow disease progression specifically for ADOA [1][2].

The Promise of NAD+ Precursors

NAD+ is a vital molecule that cells need to generate energy and stay healthy. Recent laboratory research suggests that boosting the levels of NAD+ using precursors (the building blocks that the body uses to make NAD+) like Nicotinamide Riboside (NR) or Nicotinamide Mononucleotide (NMN) might help protect the retinal cells in ADOA by improving mitochondrial function [13][14].

Enhancing the NAD+ balance is currently considered a promising area of research for ADOA [14]. However, there are currently no completed or ongoing clinical trials evaluating these specific supplements in human patients with ADOA [15][14].

Moving Forward

Currently, there are no proven, disease-modifying therapies that are standardly recommended for patients with ADOA [3]. Because their efficacy in ADOA is still under investigation, you should only consider supplements like Idebenone, CoQ10, or NAD+ precursors under the guidance of specialized medical supervision, such as a neuro-ophthalmologist or a neuro-geneticist. It is important not to self-prescribe these supplements just because they are available over-the-counter; they can present unknown safety profiles in certain conditions, interact with other medications you are taking, and create an unnecessary financial burden without proven benefit.

Instead of relying on unproven over-the-counter supplements, modern research is shifting toward precision medicine. Various genetic and RNA-based therapies are currently in preclinical research stages, aiming to address the underlying genetic mutations more directly [3][16].

While waiting for targeted therapies to advance into clinical trials, there are actionable steps you can take right now. Working with low-vision rehabilitation specialists, joining patient registries, and maintaining regular checkups with your neuro-ophthalmologist are the best ways to monitor and manage your vision health effectively [17].

Common questions in this guide

Why does Idebenone work for LHON but not ADOA?
Idebenone works for LHON because it can bypass the specific cellular energy defect that causes that disease. ADOA is typically caused by a different mutation, and research shows Idebenone is largely ineffective at protecting the optic nerve cells affected by it.
Are NAD+ precursors an effective treatment for ADOA?
While laboratory research suggests boosting NAD+ levels might help protect retinal cells, there are currently no completed or ongoing human clinical trials proving their effectiveness for ADOA. It is considered a promising area of research but not a standard treatment.
Should I take a mitochondrial cocktail for my ADOA?
There are no dedicated clinical trials confirming that mitochondrial supplement cocktails improve vision or slow progression specifically for ADOA. You should only consider taking these under the strict guidance of a specialized medical provider like a neuro-ophthalmologist.
What are the current proven treatments for ADOA?
At this time, there are no proven, standardly recommended disease-modifying therapies for ADOA. Current care focuses on working with low-vision rehabilitation specialists and monitoring your vision health through regular neuro-ophthalmologist checkups.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my specific OPA1 mutation and current vision, is there any compelling reason to try a mitochondrial supplement or 'cocktail' off-label?
  2. 2.If I decide to trial an over-the-counter NAD+ precursor like Nicotinamide Riboside, what dosage is considered safe for someone with my medical history?
  3. 3.What are the potential drug interactions between these over-the-counter supplements and my current prescribed medications?
  4. 4.Can you refer me to a low-vision rehabilitation specialist to help me maximize the use of my remaining vision?
  5. 5.Are there any active patient registries or upcoming clinical trials for genetic or RNA-based therapies that I might be eligible to join?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Autosomal Dominant Optic Atrophy Skip a Generation?Can You Drive With Autosomal Dominant Optic Atrophy?Do Hormones Worsen ADOA Vision Loss in Teenage Girls?Do Prematurity and Birth Weight Affect ADOA Symptoms?How Does Blue-Yellow Color Blindness Present in ADOA?How Does Smoking Affect Vision Loss in ADOA Patients?How is ADOA Differentiated from Normal Tension Glaucoma?Why is ADOA Misdiagnosed as a Lazy Eye in Children?ADOA vs. LHON: What Are the Key Differences?What Foods to Avoid With Autosomal Dominant Optic Atrophy?What Do ADOA Central Blind Spots Look Like? | Inciteful MedWhat Does an OCT Scan Show in ADOA? | Inciteful MedWhat If OPA1 Genetic Testing Is Negative For ADOA?What is the Risk of Total Blindness with ADOA?What is the STK-002 Clinical Trial for ADOA?When Does Hearing Loss Start in ADOA-Plus Syndrome?What Medications to Avoid with ADOA?What Support Groups and Registries Exist for ADOA?What Should I Ask a Neuro-Ophthalmologist About ADOA?

References

References (17)
  1. 1

    Leber hereditary optic neuropathy: current perspectives.

    Meyerson C, Van Stavern G, McClelland C

    Clinical ophthalmology (Auckland, N.Z.) 2015; (9()):1165-76 doi:10.2147/OPTH.S62021.

    PMID: 26170609
  2. 2

    The Role of Citicoline and Coenzyme Q10 in Retinal Pathology.

    García-López C, García-López V, Matamoros JA, et al.

    International journal of molecular sciences 2023; (24(6)) doi:10.3390/ijms24065072.

    PMID: 36982157
  3. 3

    Antisense Oligonucleotide STK-002 Increases OPA1 in Retina and Improves Mitochondrial Function in Autosomal Dominant Optic Atrophy Cells.

    Venkatesh A, McKenty T, Ali S, et al.

    Nucleic acid therapeutics 2024; (34(5)):221-233 doi:10.1089/nat.2024.0022.

    PMID: 39264859
  4. 4

    Therapeutic benefit of idebenone in Leber hereditary optic neuropathy: a systematic review and meta-analysis.

    Ribeiro PVZ, Pari Mitre L, Gauza MM, et al.

    Ophthalmic genetics 2025; (46(6)):517-522 doi:10.1080/13816810.2025.2521647.

    PMID: 40653811
  5. 5

    A viewpoint about Lenadogene nolparvovec failing to meet its primary endpoint even though it permanently corrects the m.11778G>A mutation causative of LHON.

    Panfoli I, Ravera S

    Eye (London, England) 2025; (39(11)):2110-2111 doi:10.1038/s41433-025-03856-5.

    PMID: 40394266
  6. 6

    Idebenone: Clinical Potential Beyond Neurological Diseases.

    Yi B, Zeng J, Li J, et al.

    Drug design, development and therapy 2025; (19()):7929-7946 doi:10.2147/DDDT.S515053.

    PMID: 40951694
  7. 7

    Cardioprotective effects of idebenone do not involve ROS scavenging: Evidence for mitochondrial complex I bypass in ischemia/reperfusion injury.

    Perry JB, Davis GN, Allen ME, et al.

    Journal of molecular and cellular cardiology 2019; (135()):160-171 doi:10.1016/j.yjmcc.2019.08.010.

    PMID: 31445917
  8. 8

    A randomized, placebo-controlled trial of the benzoquinone idebenone in a mouse model of OPA1-related dominant optic atrophy reveals a limited therapeutic effect on retinal ganglion cell dendropathy and visual function.

    Smith TG, Seto S, Ganne P, Votruba M

    Neuroscience 2016; (319()):92-106.

    PMID: 26820596
  9. 9

    Efficacy of a mitochondrial drug cocktail in preventing acute encephalopathy with biphasic seizures and late reduced diffusion.

    Omata T, Aoyama H, Murayama K, et al.

    Journal of the neurological sciences 2024; (466()):123245 doi:10.1016/j.jns.2024.123245.

    PMID: 39303350
  10. 10

    MORC2 gene de novo mutation leads to Charcot-Marie-Tooth disease type 2Z: A pediatric case report and literature review.

    Yang H, Yang S, Kang Q, et al.

    Medicine 2021; (100(37)):e27208 doi:10.1097/MD.0000000000027208.

    PMID: 34664855
  11. 11

    Sudden bilateral vision loss in a child with LYRM7-related leukoencephalopathy.

    Dewan L, Mupparapu V, Kekunnaya R, Chattannavar G

    Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 2025; (29(6)):104658 doi:10.1016/j.jaapos.2025.104658.

    PMID: 41045959
  12. 12

    LYRM7-associated mitochondrial complex III deficiency with non-cavitating leukoencephalopathy and stroke-like episodes.

    Alfattal R, Alfarhan M, Algaith AM, et al.

    American journal of medical genetics. Part A 2023; (191(5)):1401-1411 doi:10.1002/ajmg.a.63143.

    PMID: 36757047
  13. 13

    Preventive and Protective Effects of Nicotinamide Adenine Dinucleotide Boosters in Aging and Retinal Diseases.

    Noreen S, Lim SS, Lee D

    International journal of molecular sciences 2025; (26(22)) doi:10.3390/ijms262210923.

    PMID: 41303405
  14. 14

    Disrupted energy metabolism is associated with retinal ganglion cell degeneration in autosomal dominant optic atrophy.

    Kang EY, Tseng YJ, Peng WH, et al.

    Science advances 2026; (12(8)):eadx7815 doi:10.1126/sciadv.adx7815.

    PMID: 41706861
  15. 15

    Dominant Optic Atrophy and Leber's Hereditary Optic Neuropathy: Update on Clinical Features and Current Therapeutic Approaches.

    Chun BY, Rizzo JF

    Seminars in pediatric neurology 2017; (24(2)):129-134 doi:10.1016/j.spen.2017.06.001.

    PMID: 28941528
  16. 16

    Autosomal dominant optic atrophy: A novel treatment for OPA1 splice defects using U1 snRNA adaption.

    Jüschke C, Klopstock T, Catarino CB, et al.

    Molecular therapy. Nucleic acids 2021; (26()):1186-1197 doi:10.1016/j.omtn.2021.10.019.

    PMID: 34853716
  17. 17

    Correlation between quality of vision and clinical and structural parameters in patients with Autosomal Dominant Optic Atrophy.

    Camós-Carreras A, Figueras-Roca M, Albà-Arbalat S, et al.

    Eye (London, England) 2025; (39(9)):1837-1842 doi:10.1038/s41433-025-03762-w.

    PMID: 40140688

This page discusses supplements and experimental research for educational purposes only. Always consult your neuro-ophthalmologist before starting any new supplements or over-the-counter treatments for ADOA.

Get notified when new evidence is published on Autosomal dominant optic atrophy, classic form.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.